The interplay between genetics, the microbiome, DNA-methylation & gene-expression

Bonder, Marc Jan

Proton Pump Inhibitors Affect the Gut Microbiome

Gut, DOI:10.1136

Floris Imhann[1], Marc Jan Bonder[2*], Arnau Vich Vila[1*], Jingyuan Fu[2], Zlatan Mujagic[3], Lisa Vork[3], Ettje F. Tigchelaar[2], Soesma A. Jankipersadsing[2], Maria C. Cenit[2], Hermie J.M. Harmsen[4], Gerard Dijkstra[1], Lude Franke[2], Ramnik J. Xavier[5], Daisy Jonkers[4#], Cisca Wijmenga[2#], Rinse K. Weersma[1#], Alexandra Zhernakova[1#]*

3

Abstract

Background & Aims Proton pump inhibitors (PPI) are among the top ten most widely used drugs in the world. PPI use has been associated with an increased risk of enteric infections, most notably Clostridium difficile. The gut microbiome plays an important role in enteric infections, by resisting or promoting colonization by pathogens. In this study, we investigated the influence of PPI use on the gut microbiome.

Methods The gut microbiome composition of 1815 individuals, spanning three cohorts, was assessed by tag-sequencing of the 16S rRNA gene. The difference in microbiota composition in PPI users vs. non-users was analyzed separately in each cohort, followed by a meta-analysis.

Results 211 of the participants were using PPI at the moment of stool sampling. PPI use is associated with a significant decrease in Shannon's diversity and with changes in 20% of the bacterial taxa (FDR < 0.05). Multiple oral bacteria were overrepresented in the fecal microbiome of PPI-users, including the genus *Rothia* ($p=9.8x10^{-38}$). In PPI users we observed a significant increase in bacteria: genera *Enterococcus*, *Streptococcus*, *Staphylococcus* and the potentially pathogenic species *Escherichia coli*.

Conclusions The differences between PPI users and non-users observed in this study are consistently associated with changes towards a less healthy gut microbiome. These differences are in line with known changes that predispose to *C. difficile* infections and can potentially explain the increased risk of enteric infections in PPI users. On a population level, the effects of PPI are more prominent than the effects of antibiotics or other commonly used drugs.

Summary box

What is already known about this subject:

- PPI use is associated with increased risk of enteric infections, in particular with a 65% increase in incidence of *Clostridium difficile* infection.
- PPI is one of the most commonly used drugs.
- Changes in the gut microbiome can resist or promote the colonization of enteric infections.

What are the new findings:

- PPI use is associated with decreased bacterial richness and profound changes in the gut microbiome: 20% of the identified bacteria in this study showed significant deviation.
- Oral bacteria and potential pathogenic bacteria are increased in the gut microbiota of PPI users.
- On the population level we see more microbial alterations in the gut associated with PPI use than with antibiotics or other drug use.

How might it impact on clinical practice in the foreseeable future?

- Given the widespread use of PPI, the morbidity and mortality associated with enteric infections, and the increasing number of studies investigating the microbiome, both healthcare practitioners and researchers should take into consideration the influence of PPI on the gut microbiome

*1.University of Groningen and University Medical Center Groningen, Groningen, the Netherlands, Department of Gastroenterology and Hepatology; 2. University of Groningen and University Medical Center Groningen, Groningen, the Netherlands, Department of Genetics; 3. M aastricht University Medical Center+, Maastricht, The Netherlands, Division Gastroenterology-Hepatology, NUTRIM School for Nutrition, and Translational Research in Metabolism; 4. University of Groningen and University Medical Center Groningen, Groningen, the Netherlands, Department of Medical Microbiology; 5. Broad Institute of Harvard and MIT, Boston, USA; *Shared first authors; #Shared last authors.* ***Correspondance to****: Prof. Dr. Rinse K. Weersma, E-mail: r.k.weersma@umcg.nl*

Background & Aims

Proton pump inhibitors (PPI) are among the top ten most widely used drugs in the world. In 2013, 7% of the population of the Netherlands used omeprazole. In the same year, esomeprazole was the second largest drug in terms of revenue in the United States.[1,2] PPI are used to treat gastro-esophageal reflux disorder (GERD) and to prevent gastric and duodenal ulcers.[3,4] Of the general population, 25% report having heartburn at least once a month, explaining the large demand for PPI.[4] Nevertheless, PPI are frequently prescribed or taken for long periods without evidence-based indication.[5,6]

PPI use has been associated with increased risk of enteric infections.[5,7–9] A meta-analysis of 23 studies, comprising almost 300,000 patients, showed a 65% increase in the incidence of *Clostridium difficile*-associated diarrhea among patients who used PPI.[9] In healthcare-related settings, PPI use also increases the risk of recurrent *C. difficile* infections.[5] Another meta-analysis of 11,280 patients, from six studies evaluating *Salmonella*, *Campylobacter* and other enteric infections, also found an increased risk due to acid suppression, with a greater association with PPI than with H_2-receptor antagonists.[8] Recently, the Dutch National Institute for Public Health and the Environment (*RIVM*) noticed a marked increase in the occurrence of campylobacteriosis associated with increased PPI use in the Netherlands.[7]

The gut microbiome plays an important role in these enteric infections.[10–13] Gut microbiota can resist or promote the microbial colonization of the gut by C. difficile and other enteric infections through several mechanisms that either directly inhibit bacterial growth or enhance the immune system.[10,11] Moreover, substituting the gut microbiota of diarrhea patients with C. difficile with a healthy microbiome through faecal transplantation has been proven to cure C. difficile infection.14 The increased incidence of enteric infections in PPI users and the importance of the gut microbiome composition in the development of these infections led us to investigate the influence of PPI use on the gut microbiome.

Results

PPI use is associated to older age and higher BMI

PPI were used by 211 (11.6%) of the 1815 participants: 8.4% of the general population (Cohort 1), 20.0% of the IBD patients (Cohort 2) and 15.2% of the participants of case-control Cohort 3. Women use PPI more often than men: 9.2% versus 7.4%, albeit this was not significant ($P = 0.61$, Chi-square test). PPI users were generally older: 51.6 (SD 13.4) versus 44.4 (SD 14.7) years of age ($P = 2.50 \times 10^{-11}$, WMW test) and have a higher BMI of 26.9 (SD 5.0) versus 24.9 (SD 4.2) for non-users ($P = 1.89 \times 10^{-8}$, WMW test). Antibiotics were concomitantly used by 2% of the 99 PPI users of Cohort 1 and 33% of the 60 PPI users of Cohort 2. There was no overlap between PPI users and antibiotics users in Cohort 3. Based on our data, we included age, gender, BMI and antibiotics as co-factors in the microbiome analyses. Table 1 provides an overview of the characteristics per cohort and the use of PPI.

*Table 1. Characteristics of the three independent cohorts in this study . * unless otherwise stated, BMI = body mass index, IBD = inflammatory bowel disease, IBS = irritable bowel syndrome, PPI = Proton Pump Inhibitor, SD = standard deviation, TNF-α = tumor necrosis factor alpha, UMCG = University Medical Center Groningen, MUMC = Maastricht University Medical Center.*

	Cohort 1: LifeLines-DEEP (general population)		**Cohort 2: IBD patients UMCG**		**Cohort 3: IBS case-control study MUMC**	
	PPI users (n=99)	**Non-PPI users (n=1075)**	**PPI users (n=60)**	**Non-PPI users (n=240)**	**PPI users (n=52)**	**Non-PPI users (n=289)**
	Average (SD)*	**Average (SD)***	**Average (SD)***	**Average (SD)***	**Average (SD)***	**Average (SD)***
Age	51.94 (13.59)	44.79 (13.58)	50.87 (14.49)	42.45 (14.57)	51.94 (14.27)	44.57 (18.24)
BMI	27.73 (5.10)	25.05 (4.03)	26.14 (5.53)	25.58 (4.72)	26.24 (4.10)	24.16 (4.11)
Gender (% Male)	36.36%	42.05%	61.67%	39.17%	30.77%	33.56%
Reads per sample	48,879 (43,001)	55,884 (40,057)	51,081 (43,990)	52,970 (37,787)	43,807 (28,604)	65,842 (11,9296)
Antibiotics (%)	2.02%	1.02%	31.67%	16.67%	0.00%	1.73%
IBD (%)	0.00%	0.00%	100.00%	100.00%	0.00%	0.00%
IBS (%)	34.34%	25.77%	0.00%	0.00%	90.38%	49.48%
Diarrhea (%) (IBS-D and functional diarrhea together)	7.07%	4.47%	-	-	28.4%	17.3%
Average bowel movements per day	1.36 (0.53)	1.38 (0.61)	-	-	1.60 (0.81)	1.92 (1.11)
Anti-TNF-α (%)	-	-	38.33%	28.75%	-	-
Mesalazine (%)	-	-	26.67%	39.58%	-	-
Methotrexate (%)	-	-	16.67%	5.42%	-	-
Steroids (%)	-	-	30.00%	20.42%	-	-
Thiopurines (%)	-	-	21.67%	37.08%	-	-

Composition of the gut microbiota

The predominant phylum in each cohort was Firmicutes with abundances of 76.7%, 73.8% and 77.4% in Cohorts 1, 2 and 3, respectively. Information on the composition of the gut microbiome for all three cohorts and on all taxonomic levels is provided in Supplementary Figures S1, S2 and Supplementary Table S1. Independent of PPI use, the overall high-level bacterial composition of the gut was homogeneous in all three cohorts (by phylum, class, and order level, Spearman correlations: rho > 0.94; $P < 1.6 \times 10^{-13}$).

Reduced Diversity of the Gut Microbiome Associated with PPI Use

In all three cohorts we identified a lower species richness and lower Shannon diversity, although not significant (Cohort 1, p=0.85 ; Cohort 2, p=0.16; Cohort 3, p=0.53), however in combined analysis of all three datasets we identified moderate but significant decrease in gut alpha diversity of PPI users was observed in the meta-analysis of all 1815 gut microbiome samples: Shannon index (P = 0.01) and species richness (P = 0.02)(Supplementary Figures S3 and S4).

Meta-analysis: Differences in gut microbiome associated to PPI use

The meta-analysis across all three cohorts showed statistically significant alterations in 92 of the 460 bacterial taxa abundance (FDR < 0.05). These changes are depicted in a cladogram in Figure 1 and in a heatmap in Figure 2, and in Supplementary Figure S5. Details of each taxon, including the individual direction, coefficient, P-value and FDR for each cohort, as well as the meta-analysis, are provided in Supplementary Tables S2 and S3. Cochran's Q test was used to check for heterogeneity. None of the 92 reported associations were significantly heterogeneous at the Bonferroni corrected P-value cut off (P < 5.43 x 10-4) (Supplementary Table S2).



Figure 1. PPI-associated statistically significant differences in the gut microbiome. Meta-analysis of three independent cohorts comprising 1815 fecal samples, showing a cladogram (circular hierarchical tree) of 92 significantly increased or decreased bacterial taxa in the gut microbiome of PPI users compared to non-users (FDR < 0.05). Each dot represents a bacterial taxon. The two most inner dots represent the highest level of taxonomy in our data: the kingdoms Archea and Bacteria (prokaryotes), followed outwards by the lower levels: phylum, class, order, family, genus and species. Red dots represent significantly increased taxa. Blue dots represent significantly decreased taxa.



Figure 2. Significantly altered families in PPI users consistent in three cohorts. Meta-analysis of three independent cohorts comprising 1815 fecal samples. The heatmap shows 19 families significantly increased or decreased associated with PPI use in the gut microbiome for each cohort and for the meta-analysis (meta-analysis FDR < 0.05).



Figure 3. Principal Coordinate Analysis of 1815 gut microbiome samples and 116 oral microbiome samples. The gut microbiome of PPI users is significantly different to non-PPI users in the first Coordinate (PCoA1: P = 1.39 x 10-20, Wilcoxon test). For Principal Coordinate 1 there is a significant shift of the gut microbiome of PPI users towards the oral microbiome

The overall difference of the gut microbiome associated to PPI use was also observed in the PCoA of all the datasets together (Figure 3 and Supplementary Figure S6). The same PCoA with separate colors for each cohort has been added in Supplementary Figure S7. Notably, we observed statistically significant differences between PPI users and non-users in two principal coordinates (PCoA1: $P = 1.39 \times 10^{-20}$, PCoA3: P = 0.0004, Wilcoxon test).

Similar changes in three independent cohorts were associated to PPI use

The order Actinomycetales, families *Streptococcoceae*, *Micrococcoceae*, genus *Rothia*, and species *Lactobacillus salivarius* were increased in participants using PPI in each cohort. None of the individual cohorts contained any significantly decreased taxa (FDR < 0.05). In the general population (Cohort 1), 41 of the 829 bacterial taxa were significantly increased, including the class Gammaproteobacteria, the family *Enterococcoceae,* and the genera *Streptococcus*, *Veillonella* and *Enterococcus* (FDR < 0.05) (Supplementary Table S4). No effects due to PPI dosage were observed in the associated bacteria. In IBD patients (Cohort 2), PPI use was associated with an increase of 12 of the 667 bacterial taxa, including the family *Lactobacillaceae* as well as the genera *Streptococcus* and *Lactobacillus* (FDR < 0.05) (Supplementary Table S5). In IBS case-control Cohort 3, 18 of the 624 taxa were significantly increased, including the order Lactobacillales (FDR < 0.05) (Supplementary Table S6).

Oral cavity bacteria are more abundant in the gut microbiome of PPI users

We hypothesized that the changes in the gut microbiome associated with PPI use are caused by reduced acidity of the stomach and the subsequent survival of more bacteria that are ingested with food and oral mucus. Indeed, some of the statistically significantly increased bacteria in PPI users (e.g. *Rothia dentocariosa*, *Rothia mucilaginosa*, the genera *Scardovia* and *Actinomyces* and the family *Micrococcaceae)* are typically found in the oral microbiome.[15] By analyzing 116 oral microbiome samples from participants in Cohort 1, we could compare the overall composition of bacteria in the oral microbiome to the composition of the gut microbiome. We observed a statistically significant shift in Principal Coordinate 1 in the gut microbiome samples of the PPI users towards the oral samples, compared to non-PPI users ($P = 1.39 \times 10^{-20}$, Wilcoxon test) (Figure 3). In Supplementary Figure S8, the overrepresentation of oral cavity bacteria in the guts of PPI users is depicted in a cladogram.

PPI use is independent of bowel movement frequency and stool consistency

Some of the significantly increased taxa were more abundant in the small intestine.[11] To ensure that the changes observed in microbiota composition were not due to diarrhea and/or more frequent bowel movements, we checked in our general population whether clinical symptoms of diarrhea were more often present in PPI users. Neither diarrheal complaints (IBS-D and functional diarrhea, P = 0.22, Fisher's exact test), stool consistency as defined by the Bristol Stool Scale (rho = 0.027 P = 0.36, Spearman correlation) nor the defecation frequency (rho = -0.001, P = 0.98, Spearman correlation) of the participants in Cohort 1 were related to PPI use.

PPI, anitbiotics and other commonly used drugs

In Cohort 1, sixteen taxa were associated to antibiotics and others commonly used drug categories besides PPI (Supplementary Table S7). After correction for PPI use, only six taxa remained associated to certain drugs: statins, fibrates and drugs that change bowel movements. All 92 alterations in bacterial taxa associated to PPI use remained statistically significant if we correct the microbiome analyses for antibiotics and other commonly used drugs.

Conclusions

We show that PPI use is consistently associated with profound changes in the gut microbiome. In our study these changes were more prominent than changes associated with either antibiotics or other commonly used drugs. While PPI have proven to be useful in the prevention and treatment of ulcers and GERD, they have also been associated with an increased risk of *C. difficile*, *Salmonella* spp., *Shigella* spp., *Campylobacter* spp., and other enteric infections.[4,5,7–9] The increased risk of acquiring one of these enteric infections is likely due to changes in the PPI user's gut microbiome. Gut microbiota can resist or promote colonization of *C. difficile* and other enteric infections through mechanisms that either directly inhibit bacterial growth or enhance the immune system.[10–13] In the case of *C. difficile,* spores might be able to germinate more easily because of metabolites synthesized by certain gut bacteria.[12,13]

We hypothesized that PPI change the gut microbiome through their direct effect on stomach acid. This acidity forms one of the main defenses against the bacterial influx that accompanies ingesting food and oral mucus. PPI reduce the acidity of the stomach, allowing more bacteria to survive this barrier. We have shown here that species in the oral microbiome are more abundant in the gut microbiome of PPI users. Moreover, a study looking into the effect of PPI on the esophageal and gastric microbiome in oesophagitis and Barret's oesophagus showed similar bacterial taxa associated with PPI use, including increased levels of *Enterobacteriaceae, Micrococcaceae, Actinomycetaceae* and *Erysipelotrichaceae*.[16] Gastric bypass surgery compromises the stomach acid barrier and leads to gut microbiome changes similar to the PPI-associated alterations in this study, thereby supporting our hypothesis.[17]

We looked at the role of the gut microbiome in *C. difficile* infections, which cause 12.1% of all nosocomial infections and were responsible for half a million infections and associated with 29,000 deaths in the United States in 2011.[18,19] Virulent strains of *C. difficile* can only colonize a susceptible gut, after which toxins are produced and spores are shed. This leads to a wide spectrum of symptoms varying from mild diarrhea to fulminant relapsing diarrhea and pseudomembranous colitis.[20] Recent human, animal and in vitro studies show an overlap between the specific alterations in the gut microbiota associated with PPI use found in this study and bacterial changes that lead to increased susceptibility to *C. difficile*. The reduced alpha diversity in PPI-users is associated with increased susceptibility to *C. difficile* infection.[13,21,22] The PPI-associated decreases of the family *Ruminococcoceae* and the genus *Bifidobacterium,* as well as the PPI-associated increases of the class *Gammaproteobacteria*, the families *Enterobacteriaceae*, *Enterococcoceae, Lactobacillaceae* and the genera *Enterococcus* and *Veillonella,* have been consistently linked to increased susceptibility to *C. difficile* infection. (Table 2)[10,13,21–27]

The *Ruminococcaceae* family is significantly decreased in *C. difficile* patients and enriched in healthy controls.[22,24,26] Moreover, mice that have been treated with a mixture of antibiotics that do not become clinically ill after a challenge with *C. difficile* have higher levels of *Ruminococcaceae*.[23] Within the *Ruminococcaceae* family, the *Faecalibacterium* genus was significantly increased in patients who recovered from *C. difficile* illness, whereas it was severely decreased in *C. difficile* patients with active disease.[26] Last, a decreased *Ruminococcus torques* OTU was significantly associated with *C. difficile* infection in another study, although their OTU-picking was done using a different reference database and associations were performed using OTU-level, making direct comparisons with our study difficult.[13]

Table 2. Taxa and microbiome aspects associated with both PPI use and increased risk of C. difficile infection

Taxa or microbiome aspect	Direction that increases *C. difficile* infection risk	References of role on risk of *C. difficile* infection.
Alpha diversity	Reduced	Buffie et al. Nature. 2015 Chang et al. J. Infect. Dis. 2008 Antharam et al. J. of Clinical Microbiology. 2013
k__Bacteria p__Firmicutes c__Clostridia o__Clostridiales **f__Ruminococcaceae**	Decreased	Buffie et al. Nature. 2015. Extended Figure 3d and 3e Reeves et al. Gut Microbes. 2011 Antharam et al. J. of Clinical Microbiology. 2013. Rea et al. J. of Clinical Microbiology. 2011. Schubert et al. Mbio. 2014.
k__Bacteria p__Actinobacteria c__Actinobacteria o__Bifidobacteriales f__Bifidobacteriaceae **g__Bifidobacterium**	Decreased	Buffie et al. Nature Reviews Immunology. 2013 Rea et al. J. of Clinical Microbiology. 2011 Baines et al. J. of Antimicrobial Chemotherapy. 2013
k__Bacteria p__Firmicutes c__Bacilli o__Lactobacillales f__Enterococcaceae **g__Enterococcus**	Increased	Buffie et al. Nature. 2015 (Extended figure 3d and 3e) Antharam et al. J. of Clinical Microbiology. 2013 Rea et al. J. of Clinical Microbiology. 2011 (Fig.4) Baines et al. J. of Antimicrobial Chemotherapy. 2013 Schubert et al. Mbio. 2014
k__Bacteria p__Firmicutes c__Bacilli o__Lactobacillales **f__Lactobacillaceae**, **g__Lactobacillus**, **s__delbrueckii**, **s__plantarum** and **s__reuteri**	Increased	Buffie et al. Nature Reviews Immunology. 2013 Buffie et al. Nature. 2015 Reeves et al. Gut Microbes. 2011 Antharam et al. J. of Clinical Microbiology. 2013 Rea et al. J. of Clinical Microbiology. 2011
k__Bacteria p__Firmicutes c__Clostridia o__Clostridiales f__Veillonellaceae **g__Veillonella**	Increased	Antharam et al. The J. of Clinical Microbiology. 2013
k__Bacteria p__Proteobacteria c__ Gammaproteobacteria o__Enterobacteriales f__Enterobacteriaceae g__Escherichia **s__coli**	Increased	Antharam et al. J. of Clinical Microbiology. 2013 Reeves et al. Gut Microbes. 2011 Schubert et al. Mbio. 2014 Peterfreund et al. PLOS ONE. 2012

Species of the Bifidobacterium genus: Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium pseudocatenulatum, Bifidobacterium breve, Bifidobacterium pseudolongum, Bifidobacterium adolescentis and Bifidobacterium animalis lactis have been shown to inhibit or prevent C. difficile infection.[10] The administration of antibiotics that enhance the susceptibility to C. difficile in an in vitro model of the gut also significantly reduce the genus Bifidobacterium.[25] Moreover, active C. difficile diarrhea is associated with decreased Bifidobacteria in elderly patients.[24]

The class *Gammaproteobacteria* and the family *Enterobacteriaceae* are both significantly increased in PPI users. *Gammaproteobacteria* are enriched in *C. difficile* patients compared to healthy controls.[22] Within the class *Gammaproteobacteria*, the family *Enterobacteriaceae* dominate the murine gut microbiome after administration of clindamycin. Those mice that became clinically ill after the administration of an antibiotic cocktail containing clindamycin and a *C. difficile* challenge, had profoundly increased levels of *Enterobacteriaceae* in their gut microbiome, while mice that did not become clinically ill had a gut microbiome that predominantly consisted of Firmicutes.[23] The family Enterobacteriaceae is also increased in hamsters that were treated with clindamycin and subsequently infected with *C. difficile*.[27]

The *Enterococcus* genus, which is also more abundant in PPI-users, is significantly enriched in *C. difficile*-infected patients compared to healthy controls.[22,26] An *Enterococcus faecalis* OTU and an *Enterococcus avium* OTU are both significantly associated with increased susceptibility to *C. difficile* infections in mice.[13] Moreover, an *Enterococcus avium* OTU is also significantly associated with *C. difficile* in humans.[13] The administration of the antibiotic ceftriaxone lead to an increase in the genus *Enterococcus* and enhanced the susceptibility to *C. difficile* in an in vitro model of the gut.[25]

The increased abundance of the family *Lactobacillaceae* in PPI users was associated with increased risk of *C. difficile* infection in several studies. Mice treated with a cocktail of antibiotics (consisting of kanamycin, gentamycin, colistin, metronidazole and vancomycin), cefoperazone or a combination of clindamycin and cefoperazone have higher levels of *Lactobacillaceae in their gut*.[23] Mice treated with cefoperazone and clindamycin that developed *C. difficile* infection after being challenged with the pathogen also had a higher level of *Lactobacillaceae*.[23] Within the *Lactobacillaceae* family, the *Lactobacillus* genus is significantly enriched in *C. difficile* infection patients compared to healthy controls.[22] *Lactobacillus spp* in the gut microbiome are also associated with active *C. difficile* diarrhea in patients. [24] In contrast to these studies, the *Lactobacillus* species *Lactobacillus delbrueckii*, *Lactobacillus plantarum* and a *Lactobacillus reuteri* OTU increased colonization resistance to *C. difficile*.[10,13] However, in concordance with increased risk, a *Lactobacillus johnsonii* OTU enhanced *C. difficile* infection.[13]

Last, the *Veillonella* genus that is increased in PPI users is significantly enriched in *C. difficile* patients compared to healthy controls.[22]

The prevention of healthcare-associated *C. difficile* infections is a priority in the United States and reduction targets for 2020 have been established.[5,28] A recent study looking into the effect of PPI on the risk of developing recurrent *C. difficile* infections found that of 191 PPI users admitted to a hospital, only 47.1% had an evidence-based indication for PPI use.[5] Moreover, PPI use was discontinued in only 0.6% of the cases.[5] The U.S. Food and Drug Administration already recommends limiting PPI use to a minimum dose and duration.[29] Despite these recommendations, PPI are still often over-prescribed.[5,6] The risk of unnecessary antibiotics use is already addressed.[30] However, limiting the unnecessary use of PPI should also be considered in preventing *C. difficile* and other enteric infections.

The microbiome is being intensively studied in various diseases and conditions including IBD, IBS, obesity, old age, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).[31] PPI users are overrepresented in these groups as they more likely to have gastrointestinal complaints or experience GERD, either due to their health condition or their associated lifestyle. Prominent microbiome studies looking into obesity, IBD and NAFLD include results that researchers have contributed to the condition under study, but we show they are also associated to PPI use.[32,33] It could well be that some of the observed effects should rather have been attributed to the use of PPI. Future microbiome studies in humans should therefore always take the effect of PPI on the gut microbiome into account.

This paper reports the largest study to date investigating the influence of Proton Pump Inhibitors on the gut microbiome. The profound alterations seen in the gut microbiome could be linked to the increased risk of *C. difficile* and other enteric infections. Given the widespread use of PPI, the morbidity and mortality associated with enteric infections, and the increasing number of studies investigating the microbiome, both healthcare practitioners and microbiome researchers should be fully aware of the influence of PPI on the gut microbiome.

Methods

Cohorts

We studied the effect of PPI use on the gut microbial composition in three independent cohorts from the Netherlands. These cohorts together comprise 1815 adult individuals, including both healthy subjects and patients with gastrointestinal diseases. Cohort 1 consists of 1174 individuals who participate in the general population study LifeLines-DEEP in the northern provinces of the Netherlands.[34] Cohort 2 consists of 300 Inflammatory Bowel Disease (IBD) patients from the department of Gastroenterology and Hepatology University Medical Center Groningen (UMCG), the Netherlands. Cohort 3 consists of 189 Irritable Bowel Syndrome (IBS) patients and 152 matched controls from Maastricht University Medical Center (MUMC), the Netherlands. This study was approved by the institutional review boards of the UMCG and the MUMC (MUMC http://www.clinicaltrials.gov, NCT00775060). All participants signed an informed consent form.

Medication use

Current medication use at the time of stool collection of Cohort 1 participants was extracted from a standardized questionnaire.[35] Two medical doctors reviewed all the medication for 1174 participants. PPI use was scored if participants used omeprazole, esomeprazole, pantoprazole, lansoprazole, dexlansoprazole or rabeprazole. To exclude other possible drug effects on the gut microbiome, medication use was scored in eight categories, allowing for later correction of parameters or exclusion of certain participants. These categories were medication that: (1) changes bowel movement or stool frequency, (2) lowers triglyceride levels, (3) lowers cholesterol levels, (4) anti-diabetic medication (both oral and insulin), (5) systemic anti-inflammatory medication (excluding NSAIDs), (6) topical anti-inflammatory medication, (7) systemic antibiotics, including antifungal and antimalarial medication, and (8) antidepressants including serotonin-specific reuptake inhibitors (SSRIs), *serotonin-norepinephrine reuptake inhibitors* (SNRIs), mirtazapine, and tricyclic antidepressants (TCAs). The definitions of these categories are described in the Supplementary Appendix. Analysis of drugs used in Cohort 2 was based on the IBD-specific electronic patient record in the UMCG. Current PPI use, as well as current IBD medication (mesalazines, thiopurines, methotrexate, steroids, TNF-alpha inhibitors and other biologicals) were scored at the time of sampling by the gastroenterologist treating the IBD patient. Current PPI consumption in the IBS case-control Cohort 3 was based on self-reported questionnaires. Pseudonymized data for all three cohorts was provided to the researchers.

Gut complaints and other clinical characteristics

Information on age, gender and BMI was available for all three cohorts. In Cohort 1, gut complaints were investigated using an extensive questionnaire that included defecation frequency and the Bristol Stool Scale. Possible IBS and functional diarrhea or constipation were determined using self-reported ROME III criteria. The IBD patients in Cohort 2 were diagnosed based on accepted radiological, endoscopic, and histopathological evaluation. All the IBD cases included in our study fulfilled the clinical criteria for IBD. IBS in Cohort 3 was diagnosed by a gastroenterologist according to the ROME III criteria.

Stool and oral cavity mucus sample collection

A total of 1815 stool samples and 116 oral cavity mucus samples were collected. Cohorts 1 and 2 used identical protocols to collect the stool samples. Participants of cohort 1 and 2 were asked to collect one stool sample at home. Stool samples were frozen within 15 minutes after stool production in the participants' home freezer and remained frozen until DNA isolation. A research nurse visited all participants to collect the stool samples shortly after production and they were transported and stored at −80°C. Participants of cohort 3 were asked to bring a stool sample to the research facility within 24 hours after stool production. These samples were immediately frozen upon arrival at −80°C. Oral cavity mucus samples were collected from 116 additional healthy volunteers using buccal swab.

DNA isolation and analysis of the microbiota composition

Microbial DNA from stool samples was isolated with the Qiagen AllPrep DNA/RNA Mini Kit cat. # 80204. DNA isolation from oral cavity swabs was performed using the UltraClean microbial DNA isolation kit (cat.# 12224) from MoBio Laboratories (Carlsbad, CA, USA). To determine the bacterial composition of the stool and oral cavity mucus samples, sequencing of the variable region V4 of the 16S rRNA gene was performed using Illumina MiSeq. DNA isolation is described in the Methods section of the Supplementary Appendix

Taxonomy determination

Bacterial taxonomy was determined by clustering the sequence reads with UCLUST (version 1.2.22q) with a distance threshold of 97%, using Greengenes (version 13.8) as the taxonomy reference database. Sequencing and the determination of taxonomy are described in the Methods section of the Supplementary Appendix.

Statistical analysis

In each cohort, differentially abundant taxa in the gut microbiome between PPI users and non-PPI users were analyzed using the multivariate statistical framework MaAsLin.[33] MaAsLin performs boosted, additive, general linear models between meta-data and microbial abundance data. After running the association studies in the individual cohorts, we performed a meta-analysis of the three cohorts, using the weighted Z-score method. The Cochran's Q test was used to check for heterogeneity. The significance cut-off for the Cochran's Q test was determined by Bonferroni correction for the 92 significant results: $P < 5.43 \times 10^{-4}$. Differences in richness (the number of species within a sample), principal coordinate analyses (PCoA), and Shannon diversity analysis were determined using the QIIME microbiome analysis software.[36] The Wilcoxon test and Spearman correlations were used to identify differences in Shannon's diversity and relations between the PCoA scores of PPI users and non-PPI users, while the Chi-square test, Fisher's exact test, Spearman correlation and Wilcoxon-Mann-Whitney test (WMW test) were used to determine differences in age, gender, BMI, antibiotics use, and gut complaints between PPI users and non-users. In all the microbiome analyses, multiple test corrections were based on the false discovery rate (FDR). An FDR-value of 0.05 was used as a significance cut-off.

In addition to the PPI effect, we also tested the influence of other commonly used drugs in Cohort 1. Using MaAsLin with similar settings to those described above, we tested the microbial changes associated with the use of other drugs, with and without correction for PPI, and the changes when including these common drugs as a correcting factor in the PPI versus non-PPI analysis.

Significant results were graphically represented in cladograms using GraPhlAn.[37] More details on the statistical analysis can be found in the Methods section (Supplementary Appendix).

Correction for factors influencing the gut microbiota

Differentially abundant taxa were corrected for several parameters, which were identified by statistical analysis of cohort phenotypes or univariate MaAsLin runs and subsequently added as co-factors to the additive linear model. Analyses in the general population Cohort 1 were corrected for age, gender, BMI, antibiotics use, sequence read depth, and ROME III diagnosis (IBS-Constipation (IBS-C), IBS-Diarrhea (IBS-D), IBS-Mixed (IBS-M), IBS-Undetermined (IBS-U), functional bloating, functional constipation, functional diarrhea, or none). The analysis of IBD patients in Cohort 2 was corrected for age, gender, BMI, antibiotics use, sequence read depth, diagnosis (Crohn's disease or ulcerative colitis) combined with disease location (colon, ileum or both) and IBD medication (use of mesalazines, steroids, thiopurines, methotrexate or anti-TNF antibodies). The analysis of the IBS case-control Cohort 3 was corrected for age, gender, BMI, sequence read depth, and IBS status according to the ROME III criteria. In the meta-analysis, all microbiome data were corrected for age, gender, BMI, antibiotics use, and sequence read depth.

Author contributions

A.Z., R.K.W., C.W. and D.J. designed the study. F.I., E.F.T., S.A.J., Z.M., L.V., M.C.C., and G.D. acquired the data; F.I., M.J.B. and A.V.V. analysed and interpreted the data; F.I. drafted the manuscript; M.J.B. and A.V.V. performed the statistical analysis; A.Z., R.K.W., C.W., D.J., G.D., L.F., J.F., H.J.M.H. and R.J.X. critically revised the manuscript; A.Z., R.K.W., C.W., D.J., L.F. and J.F. obtained funding; A.Z., R.K.W., C.W. and D.J. supervised the study.

Funding

Sequencing of the LifeLines-DEEP and IBS MUMC cohorts was funded by the Top Institute Food and Nutrition grant GH001 to CW. CW is further supported by an ERC advanced grant ERC-671274, SZ holds a Rosalind Franklin fellowship (University of Groningen) and MC holds a postdoctoral fellowship from the Spanish Fundación Alfonso Martín Escudero. RKW, JF and LF are supported by VIDI grants (016.136.308, 864.13.013 and 917.14.374) from the Netherlands Organization for Scientific Research (NWO).

References

1. The Dutch Foundation for Pharmaceutical Statistics (SFK). Data and Facts on 2013. (2014).
2. Drugs.com. Top 100 sales in the United States in 2013. (2013).
3. Olbe, L., Carlsson, E. & Lindberg, P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2, 132–139 (2003).
4. Moayyedi, P. & Talley, N. J. Gastro-oesophageal reflux disease. Lancet 367, 2086–2100 (2006).
5. McDonald, E. G., Milligan, J., Frenette, C. & Lee, T. C. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern. Med. 175, 784–91 (2015).
6. Kelly, O. B., Dillane, C., Patchett, S. E., Harewood, G. C. & Murray, F. E. The Inappropriate Prescription of Oral Proton Pump Inhibitors in the Hospital Setting: A Prospective Cross-Sectional Study. Dig. Dis. Sci. 60, 2280–2286 (2015).
7. Bouwknegt, M., van Pelt, W., Kubbinga, M. E., Weda, M. & Havelaar, A. H. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use ??? An ecological study. Eurosurveillance 19, 1–6 (2014).
8. Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047–2056 (2007).
9. Janarthanan, S., Ditah, I., Adler, D. G. & Ehrinpreis, M. N. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. Am J Gastroenterol 107, 1001–1010 (2012).
10. Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 13, 790–801 (2013).
11. Kamada, N., Chen, G. Y., Inohara, N. & Núñez, G. Control of pathogens and pathobionts by the gut microbiota. Nat. Immunol. 14, 685–90 (2013).
12. Britton, R. A. & Young, V. B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146, 1547–1553 (2014).
13. Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–8 (2015).
14. van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–15 (2013).
15. Segata, N. et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 13, R42 (2012).
16. Amir, I., Konikoff, F. M., Oppenheim, M., Gophna, U. & Half, E. E. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ. Microbiol. 16, 2905–2914 (2014).
17. Zhang, H. et al. Human gut microbiota in obesity and after gastric bypass. Proc.Natl. Acad.Sci.U.S.A 106, 2365–2370 (2009).
18. Lessa, F. C. et al. Burden of Clostridium difficile Infection in the United States. (supp). N. Engl. J. Med. 372, 825–834 (2015).
19. Magill, S. S. et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. N. Engl. J. Med. 370, 1198–1208 (2014).
20. M., R., M.H., W. & D.N., G. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526–536 (2009).
21. Chang, J. Y. et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435–438 (2008).
22. Antharam, V. C. et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51, 2884–2892 (2013).
23. Reeves, A. E. et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2, 145–158 (2011).

24. Rea, M. C. et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J. Clin. Microbiol. 50, 867–875 (2012).
25. Crowther, G. S. et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 68, 168–176 (2013).
26. Schubert, A. M. et al. Microbiome Data Distinguish Patients with Clostridium difficile Infection and Non- C . difficile -Associated Diarrhea from Healthy. MBio 5, 1–9 (2014).
27. Peterfreund, G. L. et al. Succession in the Gut Microbiome following Antibiotic and Antibody Therapies for Clostridium difficile. PLoS One 7, (2012).
28. Department, H. and H. S. Request for Comments on the Proposed 2020 Targets for the National Action Plan To Prevent Health Care-Associated Infections: Road Map To Elimination (Phase I: Acute Care Hospital) Measures. (2014). Available at: https://www.federalregister.gov/articles/2014/02/25/2014-04069/request-for-comments-on-the-proposed-2020-targets-for-the-national-action-plan-to-prevent-health.
29. FDA. Drug Safety and Availability - FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). (2012). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.
30. Blaser, M. Stop the killing of beneficial bacteria. Nature 476, 393–394 (2011).
31. Mehal, W. Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 637–44 (2013).
32. Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
33. Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).
34. Tigchelaar, E. F. et al. An introduction to LifeLines DEEP: study design and baseline characteristics. bioRxiv (Cold Spring Harbor Labs Journals, 2014). doi:10.1101/009217
35. Scholtens, S. et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int. J. Epidemiol. 44, 1172–1180 (2015).
36. Caporaso, J. G. et al. correspondence QIIME allows analysis of high- throughput community sequencing data Intensity normalization improves color calling in SOLiD sequencing. Nat. Publ. Gr. 7, 335–336 (2010).
37. Asnicar, F., Weingart, G., Tickle, T. L., Huttenhower, C. & Segata, N. Compact graphical representation of phylogenetic data and metadata with GraPhlAn. PeerJ 3, e1029 (2015).
Figure Legends

Acknowledgements

We thank all the participants of the IBS, IBD and Lifelines-DEEP studies for contributing samples; Astrid Maatman, Tiffany Poon, Wilma Westerhuis, Daan Wiersum, Debbie van Dussen, Martine Hesselink and Jackie Dekens for logistics support; Timothy Tickle, Curtis Huttenhower, Alexandra Sirota, Chengwei Luo, Dirk Gevers and Aleksander Kostic for their help in training the first authors; Hendrik van Dullemen and Rinze ter Steege for including IBD patients; Marten Hofker and Eelke Brandsma for contributing to the scientific discussion and Jackie Senior and Kate Mc Intyre for editing the manuscript.

Description of supplementary data files

The following additional data are available with the online version of this paper.

Supplementary data:

Supplementary Appendix. Online Methods

Supplementary Table S1 Taxonomic comparison of cohort 1,2 and 3

Supplementary Table S2 Outcome meta-analysis: All bacterial taxa

Supplementary Table S3 Outcome meta-analysis: Annotation

Supplementary Table S4 MaAsLin results: Cohort 1 LifeLines-DEEP

Supplementary Table S5 MaAsLin results: Cohort 2 IBD UMCG

Supplementary Table S6 MaAsLin results: Cohort 3 IBS MUMC

Supplementary Table S7 Cohort 1 medication influencing the microbiome

Supplementary Figure S1 Bar charts: Gut microbiome composition phylum level

Supplementary Figure S2 Bar charts: Gut microbiome composition class level

Supplementary Figure S3 Alpha diversity: Shannon index

Supplementary Figure S4 Alpha diversity: Richness

Supplementary Figure S5 Heatmap all significant associated taxa in all cohorts

Supplementary Figure S6 PCoA component 1 and component 3

Supplementary Figure S7 PCoA separate for individual cohorts.

Supplementary Figure S8 Cladogram: Oral cavity bacteria marked